Table 1.
Efficacy of sunitinib in trials with patients treated for renal cell carcinoma and GIST
| RCC | GIST | ||||
|---|---|---|---|---|---|
| Supportive (Motzer, Michaelson, et al 2006) (n = 63) | Pivotal (Motzer, Rini, et al 2006) (n = 106) | Phase III (Motzer, Hutson, et al 2006) (n = 374) | Phase I/II (Maki et al 2005) (n = 97) | Phase III (Demetri et al 2005) (n = 207) | |
| ORR | 25 (40%) | 46 (34%) | 103 (31%) | 8 (8%) | 17 (8%) |
| SD | 18 (28%) | 24 (29%) | 160 (48%) | 36 (37%) | 37 (18%) |
| TTP | 8.7 months | 8.3 months | 11 months | 7.8 months | 6.3 months |
| OS | 16.4 months | NR | NR | 19.8 months | NR |
Abbreviations: GIST, gastrointestinal stromal tumors; NR, not reached; ORR, overall response rate; OS, overall survival; RCC, renal cell carcinoma; SD, stable disease;TTP, time to progression.